Papa Alassane Diaw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Papa Alassane Diaw has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Djibril Wade
Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formation (IRESSEF), Dakar BP 7325, Senegal
2 shared publications - Géraldine Daneau
Affiliation Immunology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
2 shared publications - Luc Kestens
Department of Biomedical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium
2 shared publications - Abdoul Aziz Diallo
Laboratory of Bacteriology, Dakar, Senegal
1 shared publication - Alioune Dieye
Immunology Service, Department of Pharmaceutical and Biological Sciences, Faculty of Medicine, Pharmacy et Odontostomatology, Cheikh Anta DIOP University, BP 11136 Dakar, Senegal
1 shared publication - Babacar Mbengue
Service of Immunology, Faculty of Medicine, Pharmacy and Odontology (FMPO), Cheikh Anta Diop University of Dakar (UCAD), Dakar, Senegal
1 shared publication
Latest Publications
- 22 March 2016
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 92 (6) , 476-484
CD4 results with a bias larger than hundred cells per microliter can have a significant impact on the clinical decision during treatment initiation of HIV patients
CD4 counts are currently used to assess HIV patients for treatment eligibility and to monitor antiretroviral response to treatment. The emerging point-of-care devices could fill an important gap in resource-limited settings. However, the accuracy of CD4-counting instruments is diverse and data on how CD4 measurement errors have an impact on clinical decisions are lacking. Clinicians were queried on the use of CD4 results in their clinical setting. Subsequently, the effect of CD4 measurement errors on treatment initiation was put in a statistical model. Based on clinical CD4 databases from Belgium, Cambodia, and Senegal, the percentage of unchanged clinical decisions was calculated (treatment initiation should start within a 3-month delay [one visit]) for escalating CD4 measurement errors, taking into account the strict or preventive application of CD4 thresholds at 350 or 500 cells/µl used by clinicians. To ensure that the treatment was initiated appropriately for at least 95% of patients, an error of 5 − 10 cells/µl was allowed. This is significantly smaller than the bias of ±50 cells/µl most clinicians considered acceptable. For limits of agreement (LOA, 1.96 x error) of 100 cells/µl, corresponding to most CD4 instrument evaluations, the misclassification rate of patients was found to be 3 − 28% at the threshold of 350 cells/µl (strict or flexible), and 13 − 20% at 500 cells/µl. The maximum allowed CD4 bias on results from new CD4 technologies should not exceed 50 cells/µl (LOA 100 cells/µl) when applied for treatment initiation, to ensure at least 72% of correct clinical decisions. © 2016 International Clinical Cytometry Society
- 22 March 2016
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 92 (6) , 476-484
CD4 results with a bias larger than hundred cells per microliter can have a significant impact on the clinical decision during treatment initiation of HIV patients
CD4 counts are currently used to assess HIV patients for treatment eligibility and to monitor antiretroviral response to treatment. The emerging point-of-care devices could fill an important gap in resource-limited settings. However, the accuracy of CD4-counting instruments is diverse and data on how CD4 measurement errors have an impact on clinical decisions are lacking. Clinicians were queried on the use of CD4 results in their clinical setting. Subsequently, the effect of CD4 measurement errors on treatment initiation was put in a statistical model. Based on clinical CD4 databases from Belgium, Cambodia, and Senegal, the percentage of unchanged clinical decisions was calculated (treatment initiation should start within a 3-month delay [one visit]) for escalating CD4 measurement errors, taking into account the strict or preventive application of CD4 thresholds at 350 or 500 cells/µl used by clinicians. To ensure that the treatment was initiated appropriately for at least 95% of patients, an error of 5 − 10 cells/µl was allowed. This is significantly smaller than the bias of ±50 cells/µl most clinicians considered acceptable. For limits of agreement (LOA, 1.96 x error) of 100 cells/µl, corresponding to most CD4 instrument evaluations, the misclassification rate of patients was found to be 3 − 28% at the threshold of 350 cells/µl (strict or flexible), and 13 − 20% at 500 cells/µl. The maximum allowed CD4 bias on results from new CD4 technologies should not exceed 50 cells/µl (LOA 100 cells/µl) when applied for treatment initiation, to ensure at least 72% of correct clinical decisions. © 2016 International Clinical Cytometry Society
- 29 July 2011
- Published by Elsevier in Journal of Immunological Methods
- Vol. 372 (1-2) , 7-13
Evaluation of a flow cytometry method for CD4 T cell enumeration based on volumetric primary CD4 gating using thermoresistant reagents
- 29 July 2011
- Published by Elsevier in Journal of Immunological Methods
- Vol. 372 (1-2) , 7-13
Evaluation of a flow cytometry method for CD4 T cell enumeration based on volumetric primary CD4 gating using thermoresistant reagents